Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article reviews research on astragalus, astragaloside IV, and telomere biology. It is informational only and is not medical advice. Not medical advice. Consult a qualified healthcare professional before starting or changing any supplement regimen, particularly if you take immunosuppressive medications or have a history of autoimmune conditions or cancer.

The decision facing buyers in this category

TA-65, the branded cycloastragenol supplement marketed on the basis of telomere research, costs roughly $100–600 per month depending on dose tier. Generic astragaloside IV extracts run closer to $15–40. Traditional astragalus root powder is cheaper still. The price spread alone makes clear there are multiple distinct value propositions being sold here, and the telomere-lengthening angle differs meaningfully from the traditional immune-support use case.

The honest question the research raises: what does the human evidence actually show about astragaloside IV, cycloastragenol, and telomere biology — and does that evidence support the significant cost premium at the top of this market?

The short answer is that the telomere hypothesis is biologically coherent and grounded in real laboratory work. The human clinical evidence, however, remains thin — primarily one open-label observational study without a placebo arm, published by researchers with financial ties to the product manufacturer. That is a different story than much of the supplement market’s framing suggests.

What astragalus is, and where Japan fits

Astragalus membranaceus — known in Japanese as ōgi (黄耆, literally “yellow leader”) and in Chinese medicine as huang qi — is a perennial leguminous plant whose dried roots have been used in East Asian traditional medicine for over two millennia. The root is a foundational ingredient in Kampo, Japan’s formalized adaptation of Chinese herbal medicine, where it appears in several major compound formulas still manufactured and prescribed by Japanese physicians today.

Hochuekkito (補中益気湯), one of the most widely prescribed Kampo formulas in Japan, lists ōgi as a primary ingredient alongside ginseng, cinnamon, and several other herbs. The clinical context for this formula is fatigue, loss of appetite, and support of physical resilience — an immune-tonic framing rather than a telomere one. Japanese public health insurance covers Hochuekkito prescriptions, and Japanese physicians have conducted clinical trials on its use in cancer-related fatigue and immune function in oncology contexts. These are studies of the whole multi-ingredient formula, not of astragaloside IV in isolation.

The key conceptual distinction is that the telomere-lengthening angle is not a traditional Kampo use of ōgi. It emerged from a separate research pathway — modern molecular biology applied to a bioactive saponin extracted from astragalus root — and the isolation and commercialization of that pathway has been primarily an American and Taiwanese research development, not a Japanese one. Buyers who assume ōgi’s traditional reputation supports the telomere marketing claims are drawing a connection the evidence does not directly support.

What astragaloside IV and cycloastragenol are

Astragalus root contains dozens of biologically active compounds. The two most studied in the context of telomere biology are:

Astragaloside IV — a glycosylated saponin found throughout astragalus root. This is the form present in most commercially available astragalus supplements and in traditional preparations of ōgi.

Cycloastragenol — the aglycone form of astragaloside IV, produced when the sugar moiety is enzymatically removed. It is more lipid-soluble than astragaloside IV and considered more bioavailable in oral supplementation. TA-65, the branded product from T.A. Sciences, contains cycloastragenol rather than astragaloside IV in its full glycoside form.

The central hypothesis connecting these compounds to longevity research: both appear to activate telomerase, the enzyme responsible for maintaining and extending telomere length in cells that express it. In vitro, both compounds have shown the ability to increase telomerase activity in human immune cells and fibroblast cell lines. The central question is whether this in vitro telomerase activation translates to meaningful telomere maintenance or measurable health effects in humans at achievable oral doses — and how large any effect would have to be to matter clinically.

What the research actually measured

In vitro and animal evidence

Laboratory evidence for astragaloside IV and cycloastragenol as telomerase activators is reasonably consistent across published work. A 2008 study by Fauce et al. in the Journal of Immunology found that cycloastragenol was associated with enhanced telomerase activity in human CD8+ T cells with shortened telomeres, and with improved proliferative capacity in those cells in culture. This research drew attention because CD8+ T cell senescence — the progressive loss of replication capacity in cytotoxic immune cells — is one of the better-characterized mechanisms of immunological aging.

In mouse models, de Jesus BB et al. published findings in Aging Cell (2011) suggesting that TA-65 administration was associated with improved healthspan markers in older mice — including skin fitness and metabolic parameters — without an observed increase in cancer incidence during the study period. That last finding matters: telomerase activation is a genuine concern in cancer biology, because cancer cells frequently upregulate telomerase to maintain their replicative potential. An intervention that broadly activates telomerase in healthy tissue carries a theoretical risk of supporting cancer cell survival, not just healthy cell survival.

The mouse data is cautiously encouraging from a safety-signal standpoint. Animal model results have a long track record of failing to replicate in human trials, and a single mouse study cannot resolve the cancer biology question for human contexts.

The Harley 2011 observational study

The most frequently cited human evidence for TA-65 is a 2011 paper by Harley CB et al. in Rejuvenation Research, titled “A natural product telomerase activator as part of a health maintenance program.”

Design and measurements:

• Subjects: approximately 100 adults enrolled in a multi-component health maintenance program
• Intervention: TA-65 (5 mg or 25 mg cycloastragenol per day) combined with diet, exercise counseling, and additional supplements
• Duration: one year
• Endpoints: telomere length distribution (specifically the proportion of critically short telomeres), immune cell phenotype markers, metabolic markers

The study reported that the proportion of critically short telomeres decreased over the year in participants, and certain immune markers shifted in directions associated with lower immunosenescence — a broad term for age-related decline in immune function.

Several limitations make it difficult to draw confident conclusions:

No placebo control arm. The comparison is within the same group of people over time, not against a concurrent placebo-receiving group. Without a placebo, changes cannot be attributed to TA-65 rather than to the other components of the health maintenance program — diet modifications, exercise, other supplements, or the engagement effect of being enrolled in a health study at all.

Author financial relationships. The senior authors have disclosed financial relationships with T.A. Sciences. The study was not conducted by an independent group without financial interest in the outcome. This does not mean the data is false, but it means independent replication is necessary before confident interpretation — and that replication has not appeared in the decade-plus since publication.

No hard clinical endpoints. Telomere length and immune cell phenotype are biomarkers, not clinical outcomes. The study was not designed or powered to measure cardiovascular events, disease incidence, or survival.

A 2013 study by Salvador et al. in Clinical Interventions in Aging examined TA-65 in approximately 100 HIV-positive patients on antiretroviral therapy and found some immune reconstitution signals. Again, without a placebo arm in the primary analysis, the attribution problem is the same.

No large placebo-controlled randomized trial measuring clinical endpoints has been completed for cycloastragenol or astragaloside IV. The human evidence base remains observational and small-scale.

The telomere length question itself

A separate issue that supplement marketing in this category rarely addresses: even if astragaloside IV reliably increased telomere length in humans, the clinical meaning of that change is not established.

The evidence base for telomere biology in aging primarily shows that critically short telomeres are associated with age-related pathology. Studies of people with genetic conditions causing premature telomere shortening confirm that pathologically short telomeres are harmful. But the inference in the other direction — that supplementally extending telomeres in people without pathological shortening will meaningfully extend healthy lifespan — is a step the current evidence does not support.

Large Mendelian randomization studies examining genetically longer telomeres — a way of using natural genetic variation to approximate what happens when people carry longer telomeres throughout life — have found a more complicated picture than the simple “longer = better” framing implies. Genetically longer telomeres appear associated with reduced cardiovascular risk but increased risk of certain cancers, suggesting that the cancer biology concern with telomerase activation may be more than theoretical. This nuance is absent from most supplement-market descriptions of telomere science.

Side effects and interactions

The safety record for astragalus in its whole-root traditional form is generally considered reasonable within the dosing used in Kampo and traditional Chinese medicine. Isolated compound use at higher concentrations requires more specific attention.

Immunosuppressive medications: Astragalus is broadly characterized as an immune-modulating herb. This creates a specific concern for individuals taking immunosuppressive medications — including transplant recipients on tacrolimus or cyclosporine, or patients on immunosuppressant biologics for autoimmune conditions. Astragalus may work against the intended immunosuppressive effect. This interaction is flagged in clinical drug interaction references and is considered potentially clinically important.

Cancer history: Because the telomerase activation mechanism theoretically supports cell replication capacity, individuals with a cancer history should discuss astragalus supplementation — particularly at high-dose cycloastragenol or astragaloside IV concentrations — with their oncologist before starting. The mouse data from the 2011 study showed no increased cancer incidence, but a single short-duration mouse study is not adequate reassurance for someone with an existing cancer history.

Pregnancy and breastfeeding: No adequate human safety data exists for concentrated astragaloside IV supplementation in pregnancy. Astragalus root appears in traditional Chinese cooking, but supplemental concentrations represent a different compound exposure level.

Lithium: Astragalus may affect renal clearance of lithium in ways that alter plasma lithium levels. Patients on lithium should not add astragalus supplements without discussing it with their prescribing physician.

At standard supplement doses, reported adverse effects are mild: occasional GI discomfort and loose stools are the most common complaints. The broader astragalus safety record from traditional use suggests reasonable tolerability, but this evidence base does not automatically extend to isolated astragaloside IV extracts at concentrated doses.

Three product tiers and what to compare

Whole astragalus root powder or standardized extract: Available from established supplement brands, these are the most conservative and affordable entry point. Products typically standardize to 0.3–0.5% astragaloside IV by weight. This format is closest to traditional Kampo ōgi root usage and carries the longest real-world consumption record.

Astragaloside IV standardized extracts: Some products concentrate astragaloside IV to 50–98% purity from astragalus root, delivering meaningfully higher concentrations of the target compound. Prices range from $20–60 per month. The oral bioavailability of concentrated astragaloside IV (glycoside form) has not been extensively characterized in published human pharmacokinetic studies — this is a gap in the available evidence.

Cycloastragenol (TA-65 and generic alternatives): The aglycone form with higher bioavailability. TA-65 branded product retails at a substantial premium ($200–600 per month for higher doses). Generic cycloastragenol products have entered the market at lower price points; quality and purity vary considerably, and the branded TA-65 is the form studied in the one published human observational trial.

Astragalus root extract supplements on Amazon include options from brands like NOW Foods, Solaray, and Nature’s Way. For astragaloside IV standardized extracts, verify the stated purity percentage and look for products with third-party certificates of analysis before buying — this is a category with meaningful quality variability. iHerb also carries several astragalus and astragaloside IV options and lists third-party testing documentation in its product pages.

The honest framing for the price decision: the human evidence for the telomere-specific claims is thin at all three tiers. The cost premium for TA-65 over generic cycloastragenol buys the form studied in the one existing observational study — the question is whether a study with those design limitations justifies the premium for any given buyer.

Who should wait before starting

• Anyone on immunosuppressive therapy (organ transplant medications, biologics for autoimmune conditions)
• Anyone with a personal cancer history, particularly cancers that may respond to proliferative signals
• Pregnant or breastfeeding women
• Anyone on lithium therapy
• Anyone already supplementing with other telomere-targeted or immune-modulating compounds (stacking effects are uncharacterized)

For adults without these factors who are interested in astragalus’s traditional Kampo context and willing to engage with early-stage human evidence on the telomere angle, whole astragalus root extract at the lower price tier is the most conservative starting point. The traditional immune-support use case for ōgi has a longer real-world record than the isolated telomere hypothesis.

The research on cycloastragenol and astragaloside IV is worth watching as the field develops. Placebo-controlled trials measuring biomarker endpoints in independently funded settings are the necessary next step. Where the evidence currently sits, the most defensible position is that astragalus root appears generally well-tolerated in traditional use contexts, and that the specific telomere hypothesis linked to astragaloside IV remains ahead of its human-evidence base by a meaningful margin.

---

See also: NMN vs NR: what human trials actually compare on dose, cost, and safety, Ashitaba and autophagy: what the Japanese chalcone research shows, CoQ10 vs ubiquinol: what cardiac RCTs and absorption data actually show.